This paper extensively studies the impact of TP53 co-mutations in EGFR mutated NSCLC homogeneously treated with EGFR TKI in first line on clinically relevant endpoints ORR, PFS and OS. The gene discussed is TP53; the disease is non-small cell lung carcinoma.